We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    allena 302
Previous Study | Return to List | Next Study

Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria (URIROX-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03847090
Recruitment Status : Terminated (Interim Analysis -)
First Posted : February 20, 2019
Last Update Posted : June 10, 2022
Sponsor:
Information provided by (Responsible Party):
Allena Pharmaceuticals

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to determine the efficacy, durability and long-term safety of reloxaliase in patients with enteric hyperoxaluria.

Condition or disease Intervention/treatment Phase
Enteric Hyperoxaluria Drug: Reloxaliase Drug: Placebo Phase 3

Detailed Description:
This is a phase 3, global, multi-center, randomized, double-blind, placebo-controlled study. This study is designed to determine the short- and long-term efficacy of reloxaliase in terms of reducing urinary oxalate excretion and clinical benefits compared to placebo.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 92 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)
Actual Study Start Date : August 26, 2019
Actual Primary Completion Date : May 19, 2022
Actual Study Completion Date : May 19, 2022
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Reloxaliase
Reloxaliase (ALLN-177) 142 mg of oxalate decarboxylase (equivalent to 3,750 units of enzyme activity) per capsule
 Drug: Reloxaliase
Reloxaliase 2 capsules, orally, with each meal/snack, 3 to 5 times per day
Other Names:
  • ALLN-177
  • Oxalate decarboxylase
Placebo Comparator: placebo
placebo capsule
 Drug: Placebo
Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day
Other Name: Placebo capsule


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percent change from baseline in 24-hour urinary oxalate excretion during Weeks 1 to 4 [ Time Frame: 4 weeks ]
    Efficacy will be assessed based on percent change from baseline to the average across Weeks 1 to 4, derived from all 24-hour collections during Weeks 1 to 4 on treatment

  2. Proportion of subjects with kidney stone disease progression (composite of symptomatic kidney stone(s) or finding of new or enlarged kidney stone(s) on imaging) [ Time Frame: up to 48 months ]
    Efficacy will be assessed by comparing kidney stone disease progression event rate on reloxaliase vs. placebo


Secondary Outcome Measures :
  1. Percent change from baseline in 24-hour urinary oxalate excretion during Weeks 16-24 [ Time Frame: 24 weeks ]
    Efficacy will be assessed based on percent change from baseline to the average across Weeks 16-24, derived from all 24-hour collections during Weeks 16-24 on treatment

  2. Proportion of subjects with a ≥ 20% reduction from baseline in 24-hour urinary oxalate excretion during Weeks 1-4 [ Time Frame: 4 weeks ]
    Efficacy will be assessed based on proportion of subjects with ≥ 20% reduction from baseline to the average across Weeks 1-4, derived from all 24-hour collections during Weeks 1-4 on treatment

  3. Hospitalizations or emergency room (ER) visits or procedures for the management of kidney stones [ Time Frame: up to 48 months ]
    Efficacy will be assessed by comparing utilization on reloxaliase vs. placebo

  4. Change in estimated glomerular filtration rate (eGFR) from baseline [ Time Frame: up to 48 months ]
    Efficacy will be assessed by comparing the rate of change in eGFR on reloxaliase vs. placebo


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provided informed consent
  2. Age 18 years or older
  3. Has an underlying enteric disorder associated with malabsorption with known or suspected history of hyperoxaluria (e.g., history of kidney stones or oxalate nephropathy)
  4. Urinary oxalate ≥ 50 mg/24 hr
  5. Has at least 1 documented kidney stone within 2 years

Exclusion Criteria:

  1. Acute renal failure or estimated glomerular filtration rate (eGFR) < 30 mL/minute/1.73 m2
  2. Has a known genetic, congenital, or other cause of kidney stones
  3. Unable or unwilling to discontinue Vitamin C supplementation >200mg daily
  4. Cannot establish baseline kidney stone burden
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03847090


Locations
Show Show 113 study locations
Sponsors and Collaborators
Allena Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: David Clark, MD Allena Pharmaceuticals Inc
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications:

Layout table for additonal information
Responsible Party: Allena Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03847090    
Other Study ID Numbers: ALLN-177-302
2018-000921-29 ( EudraCT Number )
First Posted: February 20, 2019    Key Record Dates
Last Update Posted: June 10, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Allena Pharmaceuticals:
kidney stone
hyperoxaluria
enteric hyperoxaluria
oxalate
kidney calcification